CN119733046A - 眼科疾病的治疗 - Google Patents

眼科疾病的治疗 Download PDF

Info

Publication number
CN119733046A
CN119733046A CN202411925146.7A CN202411925146A CN119733046A CN 119733046 A CN119733046 A CN 119733046A CN 202411925146 A CN202411925146 A CN 202411925146A CN 119733046 A CN119733046 A CN 119733046A
Authority
CN
China
Prior art keywords
weeks
treatment
bispecific antibody
vegf
bcva
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411925146.7A
Other languages
English (en)
Chinese (zh)
Inventor
亚伦·奥斯本
贾亚什里·萨尼
罗伯特·詹姆斯·威克特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Publication of CN119733046A publication Critical patent/CN119733046A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202411925146.7A 2018-02-06 2019-02-05 眼科疾病的治疗 Pending CN119733046A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862627103P 2018-02-06 2018-02-06
US62/627,103 2018-02-06
US201862729333P 2018-09-10 2018-09-10
US62/729,333 2018-09-10
PCT/EP2019/052704 WO2019154776A1 (en) 2018-02-06 2019-02-05 Treatment of ophthalmologic diseases
CN201980011416.4A CN111699004A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980011416.4A Division CN111699004A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗

Publications (1)

Publication Number Publication Date
CN119733046A true CN119733046A (zh) 2025-04-01

Family

ID=65352014

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202411925146.7A Pending CN119733046A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗
CN202411926524.3A Pending CN119770646A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗
CN201980011416.4A Withdrawn CN111699004A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗
CN202510108289.7A Pending CN119909169A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202411926524.3A Pending CN119770646A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗
CN201980011416.4A Withdrawn CN111699004A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗
CN202510108289.7A Pending CN119909169A (zh) 2018-02-06 2019-02-05 眼科疾病的治疗

Country Status (12)

Country Link
US (2) US20210139576A1 (enExample)
EP (1) EP3749359A1 (enExample)
JP (5) JP7005772B2 (enExample)
KR (3) KR20250166355A (enExample)
CN (4) CN119733046A (enExample)
AU (3) AU2019219004B2 (enExample)
CA (1) CA3088355A1 (enExample)
IL (1) IL276383B2 (enExample)
MX (1) MX2020007527A (enExample)
SG (1) SG11202006712XA (enExample)
TW (3) TWI831764B (enExample)
WO (1) WO2019154776A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
SG11202007130RA (en) 2018-01-26 2020-08-28 Univ California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
EP4010370A1 (en) * 2019-08-06 2022-06-15 F. Hoffmann-La Roche AG Personalized treatment of ophthalmologic diseases
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization
JP7158626B1 (ja) * 2020-09-04 2022-10-21 エフ．ホフマン－ラ ロシュ アーゲー Ｖｅｇｆ－ａ及びａｎｇ２に結合する抗体及び使用方法
WO2022057888A1 (zh) * 2020-09-17 2022-03-24 江苏恒瑞医药股份有限公司 特异性结合vegf和ang-2的双特异性抗原结合分子
WO2022212360A1 (en) * 2021-03-30 2022-10-06 Abpro Corporation Methods for treating choroidal neovascularization using anti-ang2 x vegf multi-specific antibodies
US12472148B2 (en) 2021-04-26 2025-11-18 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
JP2024534159A (ja) * 2021-08-23 2024-09-18 アビラマックス・バイオファーマ・インコーポレイテッド 導入遺伝子発現のための組成物および方法
CN117100845A (zh) * 2022-10-24 2023-11-24 景泽生物医药(合肥)股份有限公司 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2519543T (pt) 2009-12-29 2016-10-07 Emergent Product Dev Seattle Proteínas de ligação de heterodímero e suas utilizações
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
BR112013017752A8 (pt) * 2011-01-13 2018-01-09 Regeneron Pharma uso de um antagonista do vegf e formulação farmacêutica
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
PT2794905T (pt) 2011-12-20 2020-06-30 Medimmune Llc Polipéptidos modificados para estrutura de anticorpos bispecíficos
PT2838917T (pt) 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas
PE20150361A1 (es) 2012-07-13 2015-03-14 Roche Glycart Ag Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
MX363822B (es) * 2012-08-21 2019-04-04 Opko Pharmaceuticals Llc Formulaciones de liposomas.
CN105164157B (zh) 2013-04-29 2024-05-28 豪夫迈·罗氏有限公司 Fc-受体结合的修饰的非对称抗体及使用方法
KR20150063728A (ko) 2013-12-02 2015-06-10 삼성전자주식회사 항 VEGF-C/항 Ang2 이중 특이 항체
TWI738632B (zh) * 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
PL3230316T3 (pl) * 2014-12-11 2022-05-02 Bayer Healthcare Llc Leczenie zwyrodnienia plamki żółtej związanego z wiekiem z małą aktywną zmianą neowaskularyzacji naczyniówki
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
US10654922B2 (en) 2016-05-13 2020-05-19 Askgene Pharma Inc. Angiopoietin 2, VEGF dual antagonists
KR20250107275A (ko) * 2016-06-17 2025-07-11 제넨테크, 인크. 다중 특이적 항체의 정제

Also Published As

Publication number Publication date
TW202419464A (zh) 2024-05-16
TWI885720B (zh) 2025-06-01
JP7273204B2 (ja) 2023-05-12
WO2019154776A1 (en) 2019-08-15
TW202000700A (zh) 2020-01-01
IL276383A (en) 2020-09-30
EP3749359A1 (en) 2020-12-16
MX2020007527A (es) 2020-09-09
JP7005772B2 (ja) 2022-02-10
US20210139576A1 (en) 2021-05-13
JP2022046738A (ja) 2022-03-23
KR20240093772A (ko) 2024-06-24
JP2025084977A (ja) 2025-06-03
CN119770646A (zh) 2025-04-08
US20230416353A1 (en) 2023-12-28
IL276383B1 (en) 2023-09-01
AU2019219004A1 (en) 2020-07-16
TWI831764B (zh) 2024-02-11
KR20200119274A (ko) 2020-10-19
JP2025084976A (ja) 2025-06-03
CN111699004A (zh) 2020-09-22
AU2019219004B2 (en) 2025-06-05
IL276383B2 (en) 2024-01-01
CN119909169A (zh) 2025-05-02
JP2023099094A (ja) 2023-07-11
KR20250166355A (ko) 2025-11-27
JP2021506947A (ja) 2021-02-22
CA3088355A1 (en) 2019-08-15
SG11202006712XA (en) 2020-08-28
TW202535932A (zh) 2025-09-16
AU2025220842A1 (en) 2025-09-11
AU2025220841A1 (en) 2025-09-11
JP7646727B2 (ja) 2025-03-17

Similar Documents

Publication Publication Date Title
JP7646727B2 (ja) 眼科疾患の処置
TWI881273B (zh) 眼科疾病之個人化治療
JP2022101694A (ja) ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体
HK40034720A (zh) 眼科疾病的治疗
US20250326830A1 (en) Treatment of ophthalmologic diseases
HK40065038A (en) Personalized treatment of ophthalmologic diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40123799

Country of ref document: HK